Keith Fitz-Gerald | May 11, 2016 06:25AM ET
I've got some important news today regarding our favorite Human Augmentation play: Ekso Bionics Holdings Inc (OTC:EKSOD).
The company made a major announcement last week that's proof positive Ekso is on track and progressing nicely as expected. It's also something I'm extremely excited to see, for reasons I'll tell you about in a minute.
But first, I want to start by telling you what's happened and what it means for your money.
reverse stock split in preparation for a proposed listing on the Nasdaq Capital Market.
I told you this was probably in the cards a while back so this shouldn't come as a surprise. It's a great sign of things to come and an important development for both the company and your investing dollars.
What you need to do:
What you will see on your brokerage statement:
What will happen to your shares, options, and warrants:
What's next:
What this means for your money:
Uplistings and reverse splits for growing companies like Ekso are a fabulous development because they mean the company is taking the steps needed to attract not only more capital, but much bigger amounts of it. Both can be harbingers of higher prices ahead.
Let me explain.
Many institutional investors have specific price thresholds under which they cannot invest. So, despite the fact that they've got billions of dollars that need to be put to work, certain stocks are simply off limits if they're too inexpensive.
However, when a stock uplists, the new price often exceeds the threshold, which means that previously off-limits capital is suddenly fair game because the new price now meets the minimum price standard.
The other thing to think about is that uplisting isn't easy. That's important because the uplisting process effectively sorts the cash from the trash by acting as a de facto filter. Better companies list on better, more recognized exchanges where there is significantly more liquidity and, generally speaking, a far broader potential shareholder base. Inferior companies typically remain on over-the-counter (OTC) exchanges.
And, finally, better exchanges and higher liquidity translates into superior price discovery and better trading action. That's because a higher tier exchange makes it harder for day-traders, pump and dumpers, and other short-term penny bandits to ply their trade at your expense. Longer-term fundamentals, in other words, really start to matter.
Speaking of which, Ekso will release Q1 numbers today (Tuesday, May 10) after the bell. There will be a corresponding conference call starting at 4:30 p.m. ET, during which company officers will discuss business results and new developments. Obviously, I'll be listening in.
I'm very excited to see what's happening with the latest studies, FDA approvals, and clinical trials. I'm also keen to understand how the company is progressing with regard to both military and industrial markets.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.